81971-38-2

Basic information

• Product Name: 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE
• Synonyms: 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE;3-bromo-1-methyl-1,2-dihydropyridin-2-one;3-Bromo-1-methyl-1H-pyridin-2-one
• CAS NO: 81971-38-2
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.03
• Mol File: 81971-38-2.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 120-125 °C(Press: 0.5 Torr)
• Appearance: /
• Density: 1.664±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.77±0.62(Predicted)
• CAS DataBase Reference: 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(81971-38-2)
• EPA Substance Registry System: 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE(81971-38-2)

Safety Data

• Hazardous Substances Data: 81971-38-2(Hazardous Substances Data)

Usage

General Description

3-Bromo-1-methylpyridin-2(1H)-one is a chemical compound with the formula C6H6BrNO. It is a pyridinone derivative with a bromine atom and a methyl group attached to the pyridine ring. 3-BROMO-1-METHYLPYRIDIN-2(1H)-ONE is used in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and potential biological activity. It is commonly used as a building block in organic synthesis to introduce a pyridinone motif into various compounds. Additionally, it can be used as a reagent in chemical reactions to introduce a methylpyridine group into molecules. Overall, 3-Bromo-1-methylpyridin-2(1H)-one is a valuable chemical intermediate with diverse applications in the pharmaceutical and agrochemical industries.

Upstream product

• 52200-48-3 3-bromo-2-chloropyridine 
• 13466-43-8 3-bromo-pyridin-2-ol 
• 74-88-4 methyl iodide 
• 142-08-5 2-Pyridone 
• 13466-43-8 3-bromopyridin-2(1H)-one 
• 77-78-1 dimethyl sulfate 
• 694-85-9 1-methyl-2-pyridone 
• 626-55-1 3-Bromopyridine 

Downstream Products

• 1184298-12-1 3-(3-benzylsulfanyl-2-ethyl-phenyl)-1-methyl-1H-pyridin-2-one 
• 1184298-17-6 3-(3-benzylsulfanyl-2-methoxy-phenyl)-1-methyl-1H-pyridin-2-one 
• 1093628-98-8 O-[tert-Butyl] N-[2-fluoro-4-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)phenyl]carbamate 
• 20538-40-3 1-methyl-3-phenyl-piperidin-2-one 
• 1184298-18-7 2-methoxy-3-(1-methyl-2-oxo-1 ,2-dihydro-pyridin-3-yl)-benzenesulfonyl chloride 
• 1184298-19-8 3-(5-chloro-1-methyl-2-oxo-1 ,2-dihydro-pyridin-3-yl)-2-methoxy-benzenesulfonyl chloride 
• 1184298-10-9 5-chloro-thiophene-2-carboxylic acid[(S)-2-[3-(5-chloro-1-methyl-2-oxo-1 ,2-dihydro-pyridin-3-yl)-2-ethyl-benzenesulfonylamino]-3-((S)-3-methyl-morpholin-4-yl)-3-oxo-propyl]-amide 
• 1184298-13-2 3-(5-chloro-1-methyl-2-oxo-1 ,2-dihydro-pyridin-3-yl)-2-ethyl-benzenesulfonyl chloride 
• 1394348-44-7 2-chloro-5-(1-methyl-2-oxo-1,2-dihydro-pyridin-3-ylamino)-benzoic acid methyl ester 
• 13180-21-7 1-methyl-3-phenylpyridin-2(1H)-one 
• 1349798-35-1 5-bromo-1-methyl-3-phenylpyridin-2(1H)-one 
• 1349798-30-6 C₂₆H₃₀N₂O₂ 
• 284688-87-5 N-(3-methoxycarbonyladamant-1-ylcarbonyl)-(L)-4-(1'-methyl-2'-oxo-3'-pyridyl)phenylalanine methyl ester 
• 14529-54-5 3,5-dibromo-1-methyl-1H-pyridin-2-one 

Relevant articles and documents

Discovery and Optimization of Highly Selective Inhibitors of CDK5

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic human disease, but to date, only one therapy (tolvaptan) is approved to treat kidney cysts in ADPKD patients. Cyclin-dependent kinase 5 (CDK5), an atypical member of the cyclin-dependent kinase family, has been implicated as a target for treating ADPKD. However, no compounds have been disclosed to date that selectively inhibit CDK5 while sparing the broader CDK family members. Herein, we report the discovery of CDK5 inhibitors, including GFB-12811, that are highly selective over the other tested kinases. In cellular assays, our compounds demonstrate CDK5 target engagement while avoiding anti-proliferative effects associated with inhibiting other CDKs. In addition, we show that the compounds in this series exhibit promising in vivo PK profiles, enabling their use as tool compounds for interrogating the role of CDK5 in ADPKD and other diseases.

SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5

Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.

Antimalarial Inhibitors Targeting Serine Hydroxymethyltransferase (SHMT) with in Vivo Efficacy and Analysis of their Binding Mode Based on X-ray Cocrystal Structures

Target-based approaches toward new antimalarial treatments are highly valuable to prevent resistance development. We report several series of pyrazolopyran-based inhibitors targeting the enzyme serine hydroxymethyltransferase (SHMT), designed to improve microsomal metabolic stability and to identify suitable candidates for in vivo efficacy evaluation. The best ligands inhibited Plasmodium falciparum (Pf) and Arabidopsis thaliana (At) SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range (3.2-55 nM). A set of carboxylate derivatives demonstrated markedly improved in vitro metabolic stability (t1/2 > 2 h). A selected ligand showed significant in vivo efficacy with 73% of parasitemia reduction in a mouse model. Five new cocrystal structures with PvSHMT were solved at 2.3-2.6 ? resolution, revealing a unique water-mediated interaction with Tyr63 at the end of the para-Aminobenzoate channel. They also displayed the high degree of conformational flexibility of the Cys364-loop lining this channel.